APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method
APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method
复制标题
DOI：
10.1128/aac.01225-18
复制
发表时间：
2018-10-01
影响因子：
4.9
通讯作者：
Jorgensen, Karin Meinike
中科院分区：
文献类型：
--
作者：
Arendrup, Maiken Cavling;Chowdhary, Anuradha;Jorgensen, Karin Meinike
APX 001 A是首个候选药物APX 001的活性部分。到目前为止，大多数药敏试验研究都检查了0.5。APX 001 A对稀有菌种的MIC为0.5（挪威念珠菌）。APX 001 A在体外对除C外的所有种属的活性与对照药物相同或更高。krusei和C.挪威人。4株分离株为APX 001 A非WT;均为氟康唑耐药株。在除季也蒙念珠菌和念珠菌外的所有种属中观察到APX 001 A和氟康唑MIC之间的相关性。auris，并比较氟康唑MIC高、低浓度分离株。白色念珠菌、C. Dubliniensis、都柏林C.光叶C. tropicalis和C.耳。APX 001 A对大多数念珠菌和其他酵母菌种，包括C.与五个比较系统相比，WT-UL建议为常见的物种，并观察到一个新的和无法解释的相关性氟康唑敏感性。
APX001A is the active moiety of the first-in-class drug candidate APX001. So far, most susceptibility testing studies have examined 0.5. APX001A MICs against the rare species varied from 0.5 (Candida norvegensis). APX001A was equally or more active in vitro than the comparators against all species except C. krusei and C. norvegensis. Four isolates were APX001A non-WT; all were fluconazole resistant. A correlation was observed between APX001A and fluconazole MICs across all species except Candida guilliermondii and C. auris, and when comparing high and low fluconazole MIC isolates of C. albicans, C. dubliniensis, C. glabrata, C. tropicalis, and C. auris. APX001A showed promising in vitro activity against most Candida and other yeast species, including C. auris, compared to five comparators. WT-UL were suggested for the common species, and a new and unexplained correlation to fluconazole susceptibility was observed.